Please use this identifier to cite or link to this item:
Title: Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine
Author: Petry, Karl-Ulrich
Bollaerts, Kaatje
Bonanni, Paolo
Stanley, Margaret
Drury, Rosybel
Joura, Elmar
Kjaer, Susanne K.
Meijer, Chris J. L. M.
Riethmuller, Didier
Soubeyrand, Benoit
Van Damme, Pierre
Bosch Aparici, Francisco Javier
Keywords: Papil·lomavirus
Càncer de coll uterí
Cervix cancer
Issue Date: 1-Jan-2018
Publisher: Taylor & Francis Inc.
Abstract: Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low risk types 6 and 11, causing genital warts. Objective: To estimate the lifetime risk (up to the age of 75 years) for developing cervical cancer after vaccinating a HPV naive girl (e.g. 9 to 12 years old) with the 9vHPV vaccine in the hypothetical absence of cervical cancer screening. Methods: We built Monte Carlo simulation models using historical pre-screening age-specific cancer incidence data and current mortality data from Denmark, Finland, Norway, Sweden and the UK. Estimates of genotype contribution fractions and vaccine efficacy were used to estimate the residual lifetime risk after vaccination assuming lifelong protection. Results: We estimated that, in the hypothetical absence of cervical screening and assuming lifelong protection, 9vHPV vaccination reduced the lifetime cervical cancer and mortality risks 7-fold with a residual lifetime cancer risks ranging from 1/572 (UK) to 1/238 (Denmark) and mortality risks ranging from 1/1488 (UK) to 1/851 (Denmark). After decades of repetitive cervical screenings, the lifetime cervical cancer and mortality risks was reduced between 2- and 4-fold depending on the country. Conclusion: Our simulations demonstrate how evidence can be generated to support decision-making by individual healthcare seekers regarding cervical cancer prevention.
Note: Reproducció del document publicat a:
It is part of: Human Vaccines & Immunotherapeutics, 2018, vol. 14, num. 7, p. 1800-1806
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PetryKU.pdf1.13 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons